Wegovy HD 7.2mg: What Telehealth Patients Need to Know
Wegovy HD (semaglutide 7.2mg) was approved May 13, 2026 with 20.7% weight loss. Here's what it means for telehealth GLP-1 patients.
Approved: May 13, 2026 (54-day accelerated review)
Weight loss: 20.7% mean at 72 weeks
Key stat: 1 in 3 participants lost ≥25% body weight
Availability: Expected mid-2026 in single-dose pen format
What This Means for Telehealth Patients
Wegovy HD won't be immediately available through telehealth platforms — it requires a brand-name prescription and will initially be distributed through traditional pharmacy channels. However, it changes the conversation about what's possible with semaglutide at higher doses.
For telehealth patients currently on compounded semaglutide, the key takeaway is that higher doses deliver meaningfully more weight loss. If you've plateaued on standard doses, discuss options with your provider.
Current Telehealth Options
$149 first mo
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
$130/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
Liv Body · from $199/mo
Find a Telehealth Provider →Compounded medications are not FDA-approved. Paid link
The Bottom Line
Wegovy HD represents a significant advance in GLP-1 therapy, but current compounded and brand-name options already deliver strong results through telehealth. The 20.7% efficacy data validates the semaglutide mechanism at higher doses — good news for the entire category.
Sources
- FDA approval, Wegovy HD, May 13, 2026
- STEP UP trial results